Total
0
Shares
ice
Source: Recce Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) secures a US patent for its antibiotic product RECCE 327 and antiviral formulation RECCE 529
  • This is the company’s fourth of five patents to be granted, following China, Japan and Europe, with only Australia remaining
  • The US is considered the largest and most influential pharmaceutical market in the world, valued at US$339 billion (around A$461 billion)
  • On the market this morning, Recce was up 4.67 per cent and trading at $1.12 per share

Recce Pharmaceuticals (RCE) has been granted a US patent for its antibiotic product RECCE 327 and antiviral formulation RECCE 529.

This is the company’s fourth of five patent applications to be approved, following China, Japan and Europe, with only Australia remaining.

The US is considered the largest and most influential pharmaceutical market in the world, valued at US$339 billion (around A$461 billion).

Notably, the US market has developed and manufactured some of the world’s most innovative and best-selling drugs.

CEO James Graham is pleased with the anti-viral patent.

“Recce’s intellectual property portfolio continues to grow in line with our business strategy and the unprecedented global infectious disease crisis
before us,” Mr Graham said.

“We are thrilled to see that our Anti-viral patent was granted in the USA, the largest pharmaceutical market in the world; with yet further market-monopolies reinforcing the unique opportunities among a significant range of both bacterial and viral pathogens.”

Earlier this week, the company received a patent from the Chinese Patent Office.

On the market this morning, Recce was up 4.67 per cent and trading at $1.12 per share at 11:31 am AEST.

RCE by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.